Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) EPS (Weighted Average and Diluted): 2022-2023

Historic EPS (Weighted Average and Diluted) for RedHill Biopharma (RDHL) over the last 2 years, with Dec 2023 value amounting to $0.01.

  • RedHill Biopharma's EPS (Weighted Average and Diluted) rose 56144.35% to $46.11 in Q2 2023 from the same period last year, while for Jun 2023 it was $46.01, marking a year-over-year increase of 2402252.13%. This contributed to the annual value of $0.01 for FY2023, which is 108.33% up from last year.
  • Latest data reveals that RedHill Biopharma reported EPS (Weighted Average and Diluted) of $0.01 as of FY2023, which was up 108.33% from -$0.12 recorded in FY2022.
  • In the past 5 years, RedHill Biopharma's EPS (Weighted Average and Diluted) ranged from a high of $0.01 in FY2023 and a low of -$0.12 during FY2022.
  • Its 2-year average for EPS (Weighted Average and Diluted) is -$0.06, with a median of -$0.06 in 2022.
  • Data for RedHill Biopharma's EPS (Weighted Average and Diluted) shows a peak YoY surged of 108.33% (in 2023) over the last 5 years.
  • RedHill Biopharma's EPS (Weighted Average and Diluted) (Yearly) stood at -$0.12 in 2022, then skyrocketed by 108.33% to $0.01 in 2023.